Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

AusperBio completes $120 million Series C financing led by a strategic investor to advance AHB-137 toward commercialization and expand next-generation HBV therapies.

PRIVATEAug 28, 2026•about 4 hours ago

Amount Raised

$120 Million

Round Type

Series C

San FranciscoBiotechnologyHealth CareTherapeuticsBiopharma

Investors

Cdh InvestmentsYuan Bio Venture CapitalQiming Venture PartnersInno Pinnacle FundSherpa CapitalHan Kang CapitalRa Capital Management

Description

AusperBio has closed its $120 million Series C financing. The round saw participation from new investor RA Capital Management and continued support from existing investors. The financing will support the development of AHB-137 and accelerate the company's pipeline expansion. This financing marks a significant milestone for AusperBio as it works on essential therapies for chronic hepatitis B.

Company Information

Company

AusperBio

Location

San Francisco, California, United States

About

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and optimization to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.

Don't miss AusperBio's next move

Get an email the moment AusperBio raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for AusperBio's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

AusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.